SYNERGY™

Everolimus-Eluting Platinum Chromium Coronary Stent System

Heal with Confidence: Leading in Complex Patients

SYNERGY BP-DES was intentionally designed with a fast-absorbing polymer for early healing. The latest clinical data from EuroPCR continues to show low event rates with the SYNERGY BP-DES.

Fast Facts Sign Up

Indications, Safety, and Warnings

Request a Sales Rep

SENIOR Trial Safety Data with SYNERGY BP-DES in 1-Month DAPT* Cohort at 2-Years¹

Randomized, single-blind trial evaluating the SYNERGY BP-DES and the REBEL™ BMS in patients 75 years or older with a short duration of DAPT
Over 50% of patients enrolled received a 1-month DAPT regimen – largely stable patients
Statistical significant 4.5x reduction in ID-TLR with SYNERGY BP-DES vs. best-in-class REBEL™ BMS
0.6% ST with SYNERGY BP-DES

MACCE** at 2-years

Safety Data at 2-Years

*In patients eligible for 1-month DAPT in this study. Please review the SYNERGY DFU for full instructions on DAPT.
**All-cause mortality, MI, stroke, ischemia-driven TLR

SYNTAX II Trial 2-Year Results^2‡

Prospective, single-arm, multicenter, open-label trial of patients with de novo three-vessel CAD
The MACCE rate (primary endpoint) was significantly lower in SYNTAX II (13.2%) vs SYNTAX I (21.9%). (P=0.001)
SYNERGY BP-DES, physiological assessment, IVUS guidance, and contemporary PCI techniques demonstrated equivalent outcomes to CABG in patients with three-vessel disease.^† (MACCE rate of 13.2% PCI vs 15.1% CABG, P<0.001 for non-inferiority)

MACCE vs. Historical PCI - 2 Year Results

MACCE PCI vs. Historical CABG - 2 Year Results

† Angiographically-detected.

SCAAR AMI Substudy 2-Year Results^3‡

Evaluated SYNERGY BP-DES compared to all other new-generation DES in the SCAAR Registry in 36,292 patients with AMI at 2-Years
Lowest ST rate with SYNERGY BP-DES in AMI patients despite use in more complex patients and lesions

Definite Stent Thrombosis

Restenosis

All other newer generation DES included the following stents: Resolute Integrity™, Resolute Onyx™, Xience Xpedition™, PROMUS Element Plus™, Promus PREMIER™, Orsiro™, Biomatrix™, and Ultimaster™. There were 4,889 SYNERGY BP-DES patients and 31,403 ‘other new-generation DES’ patients.

CONSISTENT CTO Study 12-Month Results^4‡

Single-arm, 6 center study of 210 CTO patients evaluating primary end-point of TVF versus performance goal with the SYNERGY BP-DES
Low event rates in complex lesions (mean stent length 85.6 mm) and very symptomatic patients

Key Trial Details⁴

90.5% of patients had pre-PCI IVUS
90% CTO success rate
Very complex and symptomatic patients
- JCTO Score of 2.4
- Mean stent length 85.6 mm
- 21% diabetic patients
Significant QoL gains at 12-months following successful CTO PCI

TVF at 12-Months

CELTIC Bifurcation Study 9-Month Results^5‡

Examined outcomes of 170 patients at 8 sites in the UK treated by planned culotte stenting with the SYNERGY BP-DES and the Xience Xpedition™ PP-DES
Results showed lower composite primary endpoint, including 0% ST and low restenosis with the SYNERGY BP-DES

Composite Primary Endpoint at 9-Months

^{‡The safety and effectiveness of the SYNERGY Stent has not been established in multi-vessel disease, CTO lesions or bifurcation lesions.}

Early Healing

Advanced design for optimal healing

Clinical Outcomes

Outstanding evidence across trials

Efficiency

How design impacts economic value

Top

My account